The results from a multinational registry analysis study published in “The Lancet” has led to a new turn of events in the hydroxychloroquine (HCQ) controversy. Considering the study results, the World Health Organization (WHO) has temporarily withheld the HCQ arm of its global COVID-19 trial. Indian experts have shared mixed opinions on this withdrawal by WHO. The Study HCQ has been approved for the treatment of autoimmune diseases and malaria, but its use in patients with COVID-19 has not been completely studied, which has led to its irrational use.
Therefore, a multinational registry analysis was performed to assess the safety and efficacy of hydroxychloroquine (HCQ) and chloroquine (CQ) when combined with a second-generation macrolide for the treatment of patients with COVID-19. The registry is a compilation of data from 671 hospitals located across six continents. The patients were…
